These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

271 related items for PubMed ID: 30403705

  • 1. Serum sclerostin and irisin as predictive markers for atherosclerosis in Egyptian type II diabetic female patients: A case control study.
    Saadeldin MK, Elshaer SS, Emara IA, Maged M, Abdel-Aziz AK.
    PLoS One; 2018; 13(11):e0206761. PubMed ID: 30403705
    [Abstract] [Full Text] [Related]

  • 2. Association of irisin and FNDC5 rs16835198 G>T gene polymorphism with type 2 diabetes mellitus and diabetic nephropathy. An Egyptian pilot study.
    Khidr EG, Ali SS, Elshafey MM, Fawzy OA.
    Gene; 2017 Aug 30; 626():26-31. PubMed ID: 28479383
    [Abstract] [Full Text] [Related]

  • 3. Circulating serum irisin levels in obesity and type 2 diabetes mellitus.
    Shoukry A, Shalaby SM, El-Arabi Bdeer S, Mahmoud AA, Mousa MM, Khalifa A.
    IUBMB Life; 2016 Jul 30; 68(7):544-56. PubMed ID: 27220658
    [Abstract] [Full Text] [Related]

  • 4. Novel adipokines vaspin and irisin as risk biomarkers for cardiovascular diseases in type 2 diabetes mellitus.
    El-Lebedy DH, Ibrahim AA, Ashmawy IO.
    Diabetes Metab Syndr; 2018 Sep 30; 12(5):643-648. PubMed ID: 29673927
    [Abstract] [Full Text] [Related]

  • 5. Lower circulating irisin is associated with type 2 diabetes mellitus.
    Liu JJ, Wong MD, Toy WC, Tan CS, Liu S, Ng XW, Tavintharan S, Sum CF, Lim SC.
    J Diabetes Complications; 2013 Sep 30; 27(4):365-9. PubMed ID: 23619195
    [Abstract] [Full Text] [Related]

  • 6. Evaluating the correlation of sclerostin levels with obesity and type 2 diabetes in a multiethnic population living in Kuwait.
    Alramah T, Cherian P, Al-Khairi I, Abu-Farha M, Thanaraj TA, Albatineh AN, Safadi F, Ali H, Abdul-Ghani M, Tuomilehto J, Koistinen HA, Al-Mulla F, Abubaker J.
    Front Endocrinol (Lausanne); 2024 Sep 30; 15():1392675. PubMed ID: 38711986
    [Abstract] [Full Text] [Related]

  • 7. Irisin and leptin concentrations in relation to obesity, and developing type 2 diabetes: A cross sectional and a prospective case-control study nested in the Normative Aging Study.
    Sahin-Efe A, Upadhyay J, Ko BJ, Dincer F, Park KH, Migdal A, Vokonas P, Mantzoros C.
    Metabolism; 2018 Feb 30; 79():24-32. PubMed ID: 29108900
    [Abstract] [Full Text] [Related]

  • 8. Plasma irisin is elevated in type 2 diabetes and is associated with increased E-selectin levels.
    Rana KS, Pararasa C, Afzal I, Nagel DA, Hill EJ, Bailey CJ, Griffiths HR, Kyrou I, Randeva HS, Bellary S, Brown JE.
    Cardiovasc Diabetol; 2017 Nov 09; 16(1):147. PubMed ID: 29121940
    [Abstract] [Full Text] [Related]

  • 9. The relationship between inhibitors of the Wnt signalling pathway (sclerostin and Dickkopf-1) and carotid intima-media thickness in postmenopausal women with type 2 diabetes mellitus.
    Gaudio A, Privitera F, Pulvirenti I, Canzonieri E, Rapisarda R, Fiore CE.
    Diab Vasc Dis Res; 2014 Jan 09; 11(1):48-52. PubMed ID: 24227537
    [Abstract] [Full Text] [Related]

  • 10. Evaluation of irisin, retinol-binding protein 4, and leptin serum levels as biomarkers of macrovascular complications involvement in Saudi type 2 diabetes mellitus. A case-control study.
    Ali EY, Hegazy GA, Hashem EM.
    Saudi Med J; 2020 Dec 09; 41(12):1369-1374. PubMed ID: 33294897
    [Abstract] [Full Text] [Related]

  • 11. The association between serum irisin levels and cardiovascular disease in diabetic patients.
    Khorasani ZM, Bagheri RK, Yaghoubi MA, Chobkar S, Aghaee MA, Abbaszadegan MR, Sahebkar A.
    Diabetes Metab Syndr; 2019 Dec 09; 13(1):786-790. PubMed ID: 30641808
    [Abstract] [Full Text] [Related]

  • 12. Lower irisin level in patients with type 2 diabetes mellitus: A case-control study and meta-analysis.
    Zhang C, Ding Z, Lv G, Li J, Zhou P, Zhang J.
    J Diabetes; 2016 Jan 09; 8(1):56-62. PubMed ID: 25494632
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Distinct effects of pioglitazone and metformin on circulating sclerostin and biochemical markers of bone turnover in men with type 2 diabetes mellitus.
    van Lierop AH, Hamdy NA, van der Meer RW, Jonker JT, Lamb HJ, Rijzewijk LJ, Diamant M, Romijn JA, Smit JW, Papapoulos SE.
    Eur J Endocrinol; 2012 Apr 09; 166(4):711-6. PubMed ID: 22267280
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Sclerostin levels associated with inhibition of the Wnt/β-catenin signaling and reduced bone turnover in type 2 diabetes mellitus.
    Gaudio A, Privitera F, Battaglia K, Torrisi V, Sidoti MH, Pulvirenti I, Canzonieri E, Tringali G, Fiore CE.
    J Clin Endocrinol Metab; 2012 Oct 09; 97(10):3744-50. PubMed ID: 22855334
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.